Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-811: Pembrolizumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy in HER2-positive advanced gastric/GEJ adenocarcinoma
jRCT2080224081Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in HER2-positive gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab + trastuzumab + chemotherapy with Placebo + trastuzumab + chemotherapy (2 arms). Started Oct 2018; status: completed.
02
Drugs
03
Conditions
HER2-positive gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080224081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224081.